Accumulating evidence suggests that bone marrow-derived progenitor cells contribute to vascular healing and remodeling under physiologic and pathologic conditions. Although there is growing enthusiasm for therapeutic and diagnostic application of bone marrow-derived progenitors, there is a possibility that transplanted precursors or bone marrow cells may participate in the pathogenesis of unexpected diseases such as cancer, retinopathy, and atherosclerosis. The aim of this article is to review recent findings on bone marrow-derived progenitor cells obtained from animal models and clinical trials.
Introduction
Contrary to the conventional assumption that damaged organs are repaired only by migration and proliferation of local cells, accumulating evidence suggests that bone marrow-derived progenitor cells are mobilized into the systemic circulation and recruited to the site of tissue regeneration. In vascular lesions, recent reports documented that bone marrow-derived endothelial progenitor cells (EPCs) significantly contributed to neovascularization and re-endothelialization after acute vascular injury 1 . It was demonstrated that transplantation of autologous EPCs or unfractionated bone marrow cells is effective for the treatment of ischemic cardiovascular disease in several animal and clinical studies 2 . Consequently, bone marrow-derived progenitor cells seem to be a useful tool for vascular diseases. On the other hand, others suggested that bone marrow cells or circulating progenitor cells participate not only in repair of vascular homeostasis, but also in the pathogenesis of various diseases. In this article, we describe our recent findings and those of others that circulating progenitor cells contribute to vascular repair, new vessel formation, and also lesion formation [3] [4] [5] . In addition, we suggest that putative vascular progenitor cells could be used as therapeutic and diagnostic tools, but several issues need to be clarified before these cells are widely used as an established strategy to treat patients with cardiovascular diseases.
Origin of Smooth Muscle Cells in Vascular Lesions
For vascular diseases, pronounced accumulation of smooth muscle cells (SMCs) plays a major role in the pathogenesis. In atherosclerotic plaques, SMCs proliferate and synthesize extracellular matrix, contributing to lesion mass. In clinical treatment, percutaneous coronary interventions have widely been recognized to be the most standard therapy for coronary stenosis. However, postangioplasty restenosis has been observed
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at a constant rate after treatment and it worsens the prognosis. Moreover, SMC hyperplasia is a major cause of post coronary bypass surgery occlusion 6 and graft vasculopathy after transplantation 7 . Therefore, much effort has been taken to understand the molecular pathways that regulate SMC behavior. It has been hypothesized that SMCs in media dedifferentiate and migrate to the subendothelial space, proliferate, and contribute to atherogenesis in the process of atherosclerotic lesion formation 8 . In the same way, it has been assumed that all of the neointimal cells in postangioplasty restenosis and graft vasculopathy are derived from local medial SMCs. Thus, an extensive number of pharmacologic and gene therapies have been focused on the suppression of medial SMC migration and proliferation.
However, there are several observations that challenge the conventional hypothesis that all SMCs migrate from the media to the intimal lesion. First, very few papers have documented SMC migration across the internal elastic lamina from the tunica media to the subendothelial layer. On the other hand, many studies have shown that blood cells attach to the luminal side of the injured artery prior to the development of neointimal hyperplasia 9 . Second, it has been observed that SMCs in the media disappeared after severe injury caused by severe damage; neointima can grow rapidly after the injury 9 . In this study, it was also noted that neointimal cells were negative for mature SMC markers like myosin heavy chain, calponin, and h-caldesmon. The cells appeared to be rather hematopoietic at 1 week after injury. Third, many studies have reported that SMC hyperplasia can be prevented by blocking chemokines or adhesion molecules 10, 11 , which play a crucial role in recruiting blood cells. But these factors have little or no effect on the migration and proliferation of SMCs 10 . Fourth, neointimal SMCs express hematopoietic markers like FK506-binding protein 12, which is an interferon regulatory factor, and proinflammatory proteins 12 . These observations suggest that some of the neointimal SMCs might be derived from blood cells rather than medial cells. Recent studies support this hypothesis with several animal models [3] [4] [5] 13 .
Graft Vasculopathy
Graft vasculopathy is considered to be a robust form of atherosclerosis 7 . First, we reported the contribution of bone marrow cells to vascular lesions in graft vasculopathy 4 . In this study, heterotopic cardiac transplantation was performed between wild-type and ROSA mice, which express LacZ in all tissues 3, 5 . We transplanted the heart of wild-type mice to the abdominal aorta of recipient LacZ mice. Four weeks after transplantation, the lumen of coronary arteries of the transplanted heart and their smaller branches and arterioles narrowed due to concentric neointimal hyperplasia. The majority of the neointima were composed of recipient cells expressing LacZ. It was also observed that some of the medial SMCs, as well as endothelial cells (ECs), had been replaced by recipient cells. Immunofluorescence studies showed that LacZ-positive cells in the neointima expressed various markers for SMC, including myosin heavy chain, calponin, h-caldesmon, and α-smooth muscle actin (α-SMA) 3 . Conversely, when LacZ-positive hearts were transplanted into wild-type mice, LacZ-negative neointima developed on the LacZ-positive coronary arteries. Furthermore, in situ hybridization of the allografts from female to male mice showed that most of the neointimal cells corresponded to cells from the recipients 5 . These results indicated that the majority of the neointimal cells were derived from the recipient cells, but not from the medial cells of donor origin. Consistent with these observations, others have independently reported that recipient cells are a major source of graft vasculopathy in aortic transplantation models [14] [15] [16] [17] . Moreover, it was reported that most of the neointimal cells and ECs were derived from recipients in human transplantassociated arteriosclerosis after renal transplantation 18 . Next, to identify the potential source of recipient cells that contribute to allograft vasculopathy, bone marrow transplantation (BMT) was performed from LacZ mice to wild-type mice (BMT LacZ Wild mice). These mice , it was observed that GFP-positive cells accumulated on the luminal side of the graft coronary arteries. Immunofluorescent study showed that some of the GFP-positive cells in graft vasculopathy expressed α-SMA. These results indicate that recipient bone marrow might be
Bone Marrow Cells Contribute to Lesion Formation After Mechanical Vascular Injury
Bone marrow cells can also contribute to the pathogenesis of lesion formation after mechanical vascular injury 3, 4, 13 . For these experiments, BMT was performed from LacZ mice to wild-type mice (BMT LacZ Wild mice).
Four to 8 weeks after BMT, a large wire was inserted into the femoral artery of BMT LacZ Wild mice, leading to complete endothelial denudation and marked enlargement of the vascular lumen 9 . The cellularity of the medial layer decreased as a result of acute onset of SMC apoptosis. One week after the injury, the artery remained dilated, and LacZ-positive cells were detected at the luminal side of the injured vessels. At this point, LacZ-positive cells did not express a marker for SMCs (α-SMA) or for ECs (CD31). The dilated lumen narrowed gradually due to neointimal hyperplasia that comprised LacZ-positive SMCs 3, 13 . Four weeks after the wire injury, a significant amount of neointimal (63.0 ± 9.3%) and medial cells (45.9 ± 6.9%) was LacZ positive as determined by X-gal staining ( Figure 2 ). Immunofluorescence double staining documented that some bone marrowderived LacZ-positive cells in the neointimal lesions expressed α-SMA or CD31 13 . These results indicated that bone marrow cells might give rise to vascular cells, following mechanical endovascular injury.
Numerous reports have demonstrated that neointimal cells are heterogeneous and that SMCs in vascular lesions are composed of cells of diverse origin 13 . It has been shown that the cellular constituents of a lesion differ depending on the type of vascular injury 13 . In this study, three distinct types of mechanical injuries were compared in the same mouse model whose bone marrow had been reconstituted with that of GFP or LacZ mice 13 . After wire-mediated endovascular injury, a significant number of the neointimal and medial cells were derived from bone marrow. In contrast, marker-positive cells were seldom detected in the lesion induced by perivascular cuff placement. Only a few bone marrowderived cells could be detected in the neointima 
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following ligation of the common carotid artery. These findings suggest that the type of injury is crucial for the recruitment of bone marrow-derived cells for tissue remodeling and that bone marrow cells substantially contribute to lesion formation only when arteries are subjected to severe injury 13 . Therefore, it was predicted that circulating progenitors would only contribute to vascular remodeling in humans when arteries are subjected to severe injury. Consistent with this notion, an analysis of sex-mismatched bone marrow transplant human subjects showed that the recruitment of bone marrow-derived SMCs was observed in atherosclerotic lesions of the recipient arteries, but not in the undiseased segments 19 .
Bone Marrow might be the Origin of SMC-like Cells in Atherosclerotic Plaques
To evaluate the potential source of SMCs observed in atherosclerotic plaques, the bone marrow of 8-week-old apolipoprotein E (ApoE)−/− mice was replaced with that of GFP mice (BMT GFP ApoE−/− mice) or LacZ mice (BMT LacZ ApoE−/− mice) 3 . The recipient mice were kept with a western type diet for 8 weeks starting at 4 weeks after BMT 20 . It was observed that bone marrow-derived 
Bone Marrow-derived Progenitor Cells in Angiogenesis
In the human adult, angiogenesis is associated not only with tissue growth, but also with wound healing and reproductive functions. Angiogenesis is also implicated in the pathogenesis of a variety of disorders including diabetic retinopathies, tumors 21 , rheumatoid arthritis, psoriasis 22 , and atherosclerosis 23, 24 . Therefore, much effort has gone into understanding the molecular pathways that regulate angiogenesis and to the development of new strategies to treat refractory diseases targeting angiogenesis 21 . It is believed that new vessel formation results from sprouting of pre-existing vessels, where ECs , which was followed by numerous studies that described the diagnostic and therapeutic applications of EPCs. After that, accumulating evidence about EPCs was provided by many studies 1, 25 . EPCs were successfully incorporated into the site of angiogenesis under physiologic and pathologic angiogenesis 26 . Moreover, EPCs were shown to contribute to the repair of endothelium and the maintenance of vascular homeostasis 3, 18 . On the other hand, EPCs are also suggested to contribute to tumor-associated angiogenesis 27 , injuryassociated retinal angiogenesis 28 , and formation of microvessels in transplant arteriosclerosis 29 . Thus, there is a possibility that transplantation of bone marrowderived progenitors augments disease-associated unfavorable angiogenesis.
Fractions of Bone Marrow Cells that Contribute to Vascular Remodeling
Bone marrow includes pluripotent cells. Pluripotent cells are classified as hematopoietic stem cells (HSCs) and mesenchymal stem cells. Conventionally, HSCs were assumed to give rise only to hematopoietic lineage 30 .
Recent reports indicated that they might have the broader potential to differentiate into various cell types, such as epithelial cells 31 , cardiomyocytes 32 , and hepatocytes 33 . In our previous study, to identify the bone marrow cells that have the potential to generate vascular cells, we isolated a HSC-enriched fraction (c-Kit
) (KSL fraction) of bone marrow cells of LacZ mice by fluorescence-activated cell sorting 3 and injected 3,000 cells into lethally irradiated wild-type mice. Four weeks after bone marrow reconstitution, the femoral artery of the recipient mice was mechanically injured with a large wire 34 . At 4 weeks after the injury, the neointima and the media contained many LacZ-positive cells 3 , and some of them expressed α-SMA. LacZ-positive cells were also found to contribute to endothelial regeneration 3 . These findings suggest that the KSL fraction of bone marrow cells might have the potential to differentiate into both SMCs and ECs that participate in vascular remodeling.
In contrast, Wagers et al. extensively analyzed organs of wild-type mice whose bone marrow had been reconstituted with a single HSC 35 . Considering the results from their observation of an enormous number of sections, the authors concluded that transdifferentiation of HSCs into other lineages is an extremely rare event 35 . This apparent discrepancy could merely be derived from the analysis of noninjured vs. injured tissues in the two studies from the contribution of other cell types in the KSL fraction. A recent study on ischemic myocardium failed to detect any contribution of hematopoietic cells toward cardiac, smooth muscle, or endothelial phenotype 36 . We investigated the vascular lesion induced by wire after the bone marrow was reconstituted by a single HSC 37 . Although a single HSC showed an apprecia- 
Cell Surface Markers for EPCs
EPCs have been well studied with regard to their characteristics, molecular phenotypes, and the processes leading to their mobilization from the bone marrow and homing to sites of neovascularization 39 . Initially, human EPCs were considered to be included in the CD34 and/or AC133 (also called CD133) positive fraction of peripheral mononuclear cells (MNCs) 1 . Then, it was reported that endothelial-like cells can outgrow from nonpurified total MNCs on fibronectin-coated dish in the presence of vascular endothelial growth factor (VEGF), express Bandeiraea simplicifolia (BS)-lectin, and have the capacity of acetylated low density lipoprotein (LDL) uptake 40 .
However, it takes more than 4 days until the plated MNCs make clusters for the assay, and the BS-lectin + acetylated LDL uptake + fraction of MNCs contains heterogeneous cells. It was reported that endothelial-like cells could arise from both CD14 + and CD14− MNCs 41 .
Thus, the number of acetylated LDL +BS-lectin+ cells may not be the best indicator for the estimation of the number of functional EPCs in systemic circulation. , and another group reported that CD34−CD133+VEGFR-2+ EPC is a precursor of CD34+ CD133+VEGFR-2+ EPC, functionally more potent than these with respect to homing and vascular repair 47 .
Others reported that VEGFR-1 on EPCs is more important for angiogenesis than VEGFR-2 48 . It was also reported that murine EPCs express VEGFR-2 and vascular endothelial-cadherin 49 .
It still remains unclear how highly "EPCs" can differentiate into mature ECs phenotypically and functionally 50 . Identification of pure and real EPCs is expected.
Moreover, standardization of cell markers to identify putative EPCs is valuable to compare the number of circulating EPCs in patients from different institutes.
Markers of Smooth Muscle Progenitor Cells
The molecular mechanism of mobilization, homing, and differentiation of putative smooth muscle progenitors still remains unclear. There were few papers that described the phenotype of putative smooth muscle progenitor cells 51 . It still remains unclear whether endothelial-like cells or smooth muscle-like cells differentiate from a common vascular progenitor. Deb et al. reported that smooth muscle progenitors had high expression of β1 integrin, moderate expression of α1, and low levels of α(v)β3, and did not express α(v)β5, β2, α2β1, or α4β1 integrins 52 . In contrast, endothelial progenitors had high expression of α2β1, α(v)β3, α(v)β5, β1, and α1 and minimal expression of α4β1. The authors suggested the potential importance of integrins in mediating adherence of smooth muscle progenitors to specific extracellular matrix both in vitro and in vivo. Given the diversity of smooth muscle-like cells observed in human lesions 53 , it is likely that there are heterogeneous sources of smooth muscle-like cells 54 .
Future studies will identify the source of smooth muscle progenitors and the molecular signaling that dictates the recruitment of smooth muscle progenitors at the site of vascular repair and lesion formation 51, 55 . . On the other hand, recent papers suggested that adult stem cells can adopt a tissue-specific phenotype by cell fusion in vitro 59, 60 and in vivo 61, 62 , but not by transdifferentiation. It is possible that cell fusion can account for, at least in part, the accumulation of bone marrowderived SMC-like cells in vascular lesions 4 . Consistent with this notion, previous reports documented polyploidization of vascular SMCs in response to mechanical and humoral stimuli 63 . However, spontaneous cell fusion between recipient and donor-derived cells appeared to be a very rare event in a murine model of cardiac transplantation between LacZ and GFP mice 64 . Thus, it is likely that circulating progenitors can express vascular cell markers with and without cell fusion like putative cardiac progenitors 65 .
Therapeutic Strategies Targeting Circulating Smooth Muscle Progenitor Cells
Recent findings indicate that bone marrow-derived smooth muscle progenitor cells might represent an additional target for the treatment to prevent vascular diseases 4 . Consistent with this notion is the observation that transient myelosuppression can inhibit SMC hyperplasia in balloon-injured coronary arteries 66 . Inhibition of chemokine 10 or adhesion molecule 11 also effected to reduce neointimal formation after vascular injury. The implantation of coronary stents has been shown to reduce the risk of periprocedural complications and restenosis more than does balloon angioplasty alone 67 . However, in-stent restenosis (ISR) remains a significant clinical problem limiting the long-term success of percutaneous treatment. The principal cause is the excessive accumulation of SMCs. Recently, sirolimus-eluting stent (SES) has emerged as a promising strategy to prevent ISR. Sirolimus is a hydrophoric macrolide with immunosuppressive activity. A randomized, doubleblind trial demonstrated that the use of SES reduced the rates of restenosis and clinical events even in patients with complex lesions 68 , and the beneficial effect persisted for at least 3 years 69 . Despite increasing clinical interest in SES, the mechanism of locally delivered sirolimus to prevent ISR still remains undetermined 70 .
Recently, we reported that sirolimus potently inhibits differentiation of human vascular progenitor cells 71 .
The potent inhibitory effects of sirolimus on circulating smooth muscle progenitor cells may, at least in part, mediate the clinical efficacy of SES. On the other hand, sirolimus may potentially affect re-endothelialization after stent implantation, causing late thrombosis after interruption of antiplatelet therapy 72 .
It may be possible to develop gene therapies to vascular diseases that target vascular progenitor cells. One potential approach could involve the Fas/Fas ligand (FasL) system 73, 74 . Fas is a death receptor that transmits an apoptosis-inducing signal when its ligand, FasL, is activated 75, 76 . Overexpression of FasL inhibited infiltration of inflammatory cells and reduced neointimal formation after vascular injury [77] [78] [79] . FasL induces apoptosis in Fas-bearing vascular SMC 77 , while ECs are refractive to FasL overexpression 77, 80, 81 . Thus, FasL overexpression induces apoptotic cell death of SMCs and reduces lesion formation, while re-endothelialization at this same site would not be inhibited 77, 82 . Moreover, local delivery of FasL should be predicted to kill bone marrow-derived progenitor cells as well as inflammatory cells at these lesions because these cells express Fas 79, 80 . It was also reported that cell surface overexpression of FasL in ECs by transgenic approach attenuated homing of hematopoietic cells in a model of rodent transplant vasculopathy 78 . These vessels also displayed reduced neointimal formation 78 . It is conceivable that EC-specific overexpression of FasL inhibits transplant arteriosclerosis by preventing accumulation of smooth muscle progenitors, at least in part.
Therapeutic Application of Bone Marrow-derived Progenitor Cells for Vascular Disease
There is increasing enthusiasm for the use of adult stem cells for "cell transplantation therapy" and "tissue engineering" 83, 84 . It was reported that chronic treatment with bone marrow-derived progenitor cells from young nonatherosclerotic ApoE−/− mice prevented atherosclerosis progression in ApoE−/− recipients despite persistent hypercholesterolemia, presumably by facilitating re-endothelialization on recipient arteries in areas at risk for atherosclerotic injury 43 . However, given the pluripotency of adult stem cells, they may potentially 86, 87 . Thus, we should pay attention to potential adverse effects as well as beneficial aspects caused by the transplanted stem cells in the clinic.
The effects and safety of therapeutic angiogenesis by bone marrow cell transplantation for ischemic limbs 88 or ischemic heart disease [89] [90] [91] have been described in many papers. Initially, it was suggested that the functional prevention was caused by corporation of bone marrow cells to formation of new vessels in the ischemic tissues. However, recently, it has been considered that the more critical function of transplanted bone marrow cells to angiogenesis is the paracrine release of proangiogenic factors, not transdifferentiation to ECs [92] [93] [94] [95] . As mentioned above, bone marrow-derived progenitor cells are also associated with pathologic angiogenesis or atherosclerotic lesion formation (Figure 4) . A recent clinical trial with myocardial infarction patients showed that granulocyte colony-stimulating factor mobilization of stem cells and subsequent infusion of such cells improved cardiac performance and angiogenesis 96 .
However, this improvement was associated with an unexpectedly high rate of ISR, which led to premature termination of the trial. Similarly, bone marrow-derived MNCs have been shown to accelerate atherosclerosis in ApoE−/− mice 97 .
Apart from these few studies, almost all the other clinical trials did not report any negative effects, such as pathologic angiogenesis or acceleration of atherosclerosis. Three papers about bone marrow cell therapy for acute myocardial infarction (AMI) were published [98] [99] [100] . In these papers, bone marrow cells were infused intracoronarily after successful percutaneous intervention in AMI patients, and contractile function of the left ventricle (LV) was observed after 3 months 98 , 4 months 99 , 6 months 100 , and 1 year 99 . Two of these studies suggested the improvement of LV contraction by bone marrow cell infusion 98, 99 , but the other one failed to provide the effect. None of them detected unfavorable effects, which might be caused by transplantation of bone marrow-derived cells. However, the safety of BMT should be monitored for a longer time.
It is expected that the mechanistic clarity of the positive and negative effects of bone marrow-derived . Moreover, it would be important to transplant appropriate fractions of progenitors at optimal doses for regenerative medicine, and differentiation and localization of transplanted progenitors should be monitored to prevent unfavorable outcomes.
In summary, current findings indicate that bone marrow cells can contribute not only to the healing process of injured arterial wall, but also to pathologic vascular remodeling. These findings may provide the basis for the development of new therapeutic strategies for vascular disease that involve targeting the mobilization, homing, differentiation, and proliferation of bone marrow-derived vascular progenitor cells. Bone marrow cells will also be a useful therapeutic tool for ischemic diseases, but unexpected effects may occur. Therefore, further experiments that dissect the molecular mechanisms by which progenitors are recruited and differentiated at the site of injury are warranted.
